tetano
Editor, Senior Moderator
J Bronchology Interv Pulmonol
. 2022 Apr 1;29(2):146-154.
doi: 10.1097/LBR.0000000000000805.
Bronchoscopy in Patients With Known or Suspected COVID-19: Results From the Global Pandemic SARS-CoV-2 Bronchoscopy Database (GPS-BD)
Gustavo Cumbo-Nacheli[SUP] 1 [/SUP], Henri Colt[SUP] 2 [/SUP], Abhinav Agrawal[SUP] 3 [/SUP], Joseph Cicenia[SUP] 4 [/SUP], Lorenzo Corbetta[SUP] 5 [/SUP], Akhil D Goel[SUP] 6 [/SUP], Ameena Goga[SUP] 7 [/SUP], Hans J Lee[SUP] 8 [/SUP], Septimiu Murgu[SUP] 9 [/SUP], Jasleen Pannu[SUP] 10 [/SUP], Michal Senitko[SUP] 11 [/SUP], Francesco Tarantini[SUP] 12 [/SUP], Patricia Vujacich[SUP] 13 [/SUP], Jonathan Williamson[SUP] 14 15 [/SUP], Elaine Yap[SUP] 16 [/SUP], Robert J Lentz[SUP] 17 18 [/SUP]
Affiliations
Abstract
Background: Amid the Coronavirus Disease 2019 (COVID-19) pandemic, the benefits and risks of bronchoscopy remain uncertain. This study was designed to characterize bronchoscopy-related practice patterns, diagnostic yields, and adverse events involving patients with known or suspected COVID-19.
Methods: An online survey tool retrospectively queried bronchoscopists about their experiences with patients with known or suspected COVID-19 between March 20 and August 20, 2020. Collected data comprised the Global Pandemic SARS-CoV-2 Bronchoscopy Database (GPS-BD). All bronchoscopists and patients were anonymous with no direct investigator-to-respondent contact.
Results: Bronchoscopy procedures involving 289 patients from 26 countries were analyzed. One-half of patients had known COVID-19. Most (82%) had at least 1 pre-existing comorbidity, 80% had at least 1 organ failure, 51% were critically ill, and 37% were intubated at the time of the procedure. Bronchoscopy was performed with diagnostic intent in 166 (57%) patients, yielding a diagnosis in 86 (52%). and management changes in 80 (48%). Bronchoscopy was performed with therapeutic intent in 71 (25%) patients, mostly for secretion clearance (87%). Complications attributed to bronchoscopy or significant clinical decline within 12 hours of the procedure occurred in 24 (8%) cases, with 1 death.
Conclusion: Results from this international database provide a widely generalizable characterization of the benefits and risks of bronchoscopy in patients with known or suspected COVID-19. Bronchoscopy in this setting has reasonable clinical benefit, with diagnosis and/or management change resulting from about half of the diagnostic cases. However, it is not without risk, especially in patients with limited physiological reserve.
. 2022 Apr 1;29(2):146-154.
doi: 10.1097/LBR.0000000000000805.
Bronchoscopy in Patients With Known or Suspected COVID-19: Results From the Global Pandemic SARS-CoV-2 Bronchoscopy Database (GPS-BD)
Gustavo Cumbo-Nacheli[SUP] 1 [/SUP], Henri Colt[SUP] 2 [/SUP], Abhinav Agrawal[SUP] 3 [/SUP], Joseph Cicenia[SUP] 4 [/SUP], Lorenzo Corbetta[SUP] 5 [/SUP], Akhil D Goel[SUP] 6 [/SUP], Ameena Goga[SUP] 7 [/SUP], Hans J Lee[SUP] 8 [/SUP], Septimiu Murgu[SUP] 9 [/SUP], Jasleen Pannu[SUP] 10 [/SUP], Michal Senitko[SUP] 11 [/SUP], Francesco Tarantini[SUP] 12 [/SUP], Patricia Vujacich[SUP] 13 [/SUP], Jonathan Williamson[SUP] 14 15 [/SUP], Elaine Yap[SUP] 16 [/SUP], Robert J Lentz[SUP] 17 18 [/SUP]
Affiliations
- PMID: 35318989
- DOI: 10.1097/LBR.0000000000000805
Abstract
Background: Amid the Coronavirus Disease 2019 (COVID-19) pandemic, the benefits and risks of bronchoscopy remain uncertain. This study was designed to characterize bronchoscopy-related practice patterns, diagnostic yields, and adverse events involving patients with known or suspected COVID-19.
Methods: An online survey tool retrospectively queried bronchoscopists about their experiences with patients with known or suspected COVID-19 between March 20 and August 20, 2020. Collected data comprised the Global Pandemic SARS-CoV-2 Bronchoscopy Database (GPS-BD). All bronchoscopists and patients were anonymous with no direct investigator-to-respondent contact.
Results: Bronchoscopy procedures involving 289 patients from 26 countries were analyzed. One-half of patients had known COVID-19. Most (82%) had at least 1 pre-existing comorbidity, 80% had at least 1 organ failure, 51% were critically ill, and 37% were intubated at the time of the procedure. Bronchoscopy was performed with diagnostic intent in 166 (57%) patients, yielding a diagnosis in 86 (52%). and management changes in 80 (48%). Bronchoscopy was performed with therapeutic intent in 71 (25%) patients, mostly for secretion clearance (87%). Complications attributed to bronchoscopy or significant clinical decline within 12 hours of the procedure occurred in 24 (8%) cases, with 1 death.
Conclusion: Results from this international database provide a widely generalizable characterization of the benefits and risks of bronchoscopy in patients with known or suspected COVID-19. Bronchoscopy in this setting has reasonable clinical benefit, with diagnosis and/or management change resulting from about half of the diagnostic cases. However, it is not without risk, especially in patients with limited physiological reserve.